- Iain McGill
- Giovanna Lombardi
- % Shareholding
- Number of employees
- Raised in an expanded Series A in February 2021
Unless stated all figures at 31 March 2021
Quell Therapeutics was founded with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system.
Quell was founded in partnership with six prominent immunological experts from King’s College London, University College London and Hannover Medical School, and is led by Iain McGill, a seasoned pharmaceutical and biotech executive.
Tregs are capable of down regulating the immune system by ‘putting on a brake’ to prevent over activation and resultant pathological immune responses.
Quell is employing proprietary and innovative technologies to genetically enhance Tregs, to target them to particular sites within the body, for example to the liver in their lead programme in liver transplantation. These engineered Tregs have the potential to control unwanted immune activity which may enable the treatment of patients with autoimmune and inflammatory disease as well as the potential to prevent organ rejection without taking immunosuppressive medication; making transplantation the full cure it was always intended to be.
- Current standard of care for prevention of solid organ transplant rejection is life-long immunosuppression which results in an array of serious long-term side effects, such as kidney toxicity, infections and cancer, significantly impacting patient quality of life*
- Potential pipeline to treat serious, chronic conditions mediated by the immune system
- Potential to be first-in-class in CAR Tregs; an early mover in the space
- 15,000 liver transplants p.a across US and Europe**
Unmet medical need
- First programme addressing solid organ transplant; current standard of care to prevent transplant rejection is life-long immunosuppression, resulting in long-term side effects which materially impact quality of life and long-term survival
- Highly innovative concept in an emerging field
- Complex manufacturing
** Source: OPTN/SRTR 2016 Annual Data report: Liver; EDQM Volume 20 2015
The Quell Therapeutics pipeline
Liver transplant - QEL-001
Undisclosed Program QEL-002
Multiple undisclosed research programmes